Categories Earnings, Health Care

Pfizer beats Q4 revenue estimates; earnings miss expectations

Pfizer Inc. (NYSE: PFE) topped revenue expectations for the fourth quarter of 2019 while earnings missed the mark. Shares fell 1.6% in premarket hours on Tuesday.

Total revenue of $12.7 billion was down 9% from the same period a year ago but above estimates of $12.6 billion.  

On a GAAP basis, the company reported a loss of $337 million, or $0.06 per share, compared to a loss of $394 million, or $0.07 per share, in the prior-year period. Adjusted income declined 17% to $3.1 billion. Adjusted diluted EPS fell 13% to $0.55, missing the forecasts of $0.57.  

During the quarter, revenues in the Biopharma segment increased 7% to $10.5 billion while revenues in the Upjohn division fell 32% to $2.1 billion versus the year-ago quarter. Biopharma revenues rose 9% on an operational basis, driven by increases in Eliquis, Ibrance, Inlyta, Xeljanz and Xtandi. Revenues in Upjohn declined 32% due to volume declines for Lyrica in the US due to generic competition.  

For the full year of 2020, revenues are expected to be $48.5 billion to $50.5 billion. Adjusted EPS is expected to be $2.82-2.92.

Also read: Pfizer Q4 2019 Earnings Preview

Dr. Albert Bourla, Chairman and CEO, stated, “2020 is expected to be an exciting year for Pfizer with the close of the Upjohn-Mylan transaction anticipated by mid-year, leaving New Pfizer positioned to deliver revenue and adjusted diluted EPS growth that is expected to be among the industry leaders. New Pfizer will be a smaller, science-based company with a singular focus on innovation while also continuing to allocate significant capital directly to shareholders, primarily through dividends.”

Also Read:  JPM Earnings: All you need to know about JPMorgan Chase & Co. Q3 2020 earnings results

Starting from 2020, Upjohn began managing Pfizer’s Meridian subsidiary and the Mylan-Japan collaboration for generic drugs in Japan. As a result, revenues and expenses associated with these two businesses will be reported in the Upjohn division from the first quarter of 2020.

For FY2020, revenues for New Pfizer are expected to be $40.7 billion to $42.3 billion while adjusted EPS is expected to be $2.25-2.35.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Thermo Fisher Scientific (TMO) Earnings: 3Q20 Key Numbers

Thermo Fisher Scientific Inc. (NYSE: TMO) reported third quarter 2020 earnings results today. Revenue increased 36% year-over-year to $8.52 billion. GAAP earnings jumped 157% to $1.93 billion, or $4.84 per

Infographic: Snap (SNAP) Q3 2020 earnings results in a nutshell

Snap Inc. (NYSE: SNAP) reported third quarter 2020 earnings results today. Revenues increased 52% year-over-year to $679 million. Net loss amounted to $200 million, or $0.14 per share, compared to

Infographic: Netflix (NFLX) adds 2.2 mln subscribers in Q3; stock falls on earnings miss

Video streaming giant Netfllix Inc. (NASDAQ: NFLX) reported a 23% growth in third-quarter revenues as it continued to expand the subscriber base. Earnings increased but missed Wall Street’s prediction and

One thought on “Pfizer beats Q4 revenue estimates; earnings miss expectations

Comments are closed.

Top